Areas of Practice

Fabrizio Scaparro is a highly accomplished lawyer and commercially oriented negotiator who focuses on M&A, private equity, and corporate law across industries. A sought-after dealmaker, Fabrizio advises private equity sponsors and multinational corporations on a range of domestic and cross-border transactions, including acquisitions, divestitures, leveraged buyouts, joint ventures, and minority investments in public and private companies.

Fabrizio works with clients across the healthcare, technology, business services, consumer, chemical, and industrial sectors. In addition to his deal work, Fabrizio has extensive experience leading clients through pivotal business changes. These include debt restructurings, corporate reorganizations, IPOs, rights and debt offerings, and securities buy‐backs.

Clients rely on Fabrizio for his keen negotiation skills and attention to their needs. Feedback in Chambers notes that he has a calm and effective way of guiding clients. Fabrizio has received numerous accolades for his work on behalf of clients, including from Chambers, Legal500 and IFLR1000.

Fabrizio’s background includes working at leading international firms (in Milan and New York), prior to founding a leading Italian firm.

Experience

  • Alto Partners, on multiple transactions, including:
    • the acquisition of a majority stake in Fragesa, operating a leading chain of Italian pizzerias under the brand “Fradiavolo”*
    • the acquisition by Eurofiere (an Alto Partners’ portfolio company), leading contract manufacturer for trade and exhibition fittings, of the entire corporate capital of (i) Form, and (ii) A&M Productions*
  • A consortium formed by Alto Partners and Arca Gestioni SGR S.p.A., through the fund Arca Space Capital, on the acquisition of the entire share capital of Eurosirel, a leading CDMO for healthcare and cosmetic sectors*
  • Ambienta, on the acquisition of PIECO, a leading global provider of industrial water treatment and recycling solutions*
  • Animalia, the leading Italian operator of veterinary clinics and a portfolio company of Charme Capital Partners, on multiple transactions, including:
    • the sale of a majority stake of Animalia to Charme Capital Partners*
    • a buy-and-build project through the acquisition of several (more than 50 to date and counting) veterinary clinics and the creation of a leading Italian network of veterinary clinics*
  • Ardian, on multiple transactions, including:
    • the acquisition of the entire share capital of Italmatch Chemicals, a leading global specialty chemicals group*
    • the acquisition of Irca, leading manufacturer of ingredients for the bakery and ice cream sectors*
    • the acquisition of a majority stake in Dedalus Group, leading provider of IT solutions for the healthcare sector*
    • the acquisition of a majority stake of Neopharmed Gentili, leading Italian pharmaceutical distributor*
    • the sale of Italmatch Chemicals, a leading global specialty chemicals group, to Bain Capital*
    • the sale of Irca, leading manufacturer of ingredients for the bakery and ice cream sectors, to The Carlyle Group*
    • the acquisition of the entire share capital of Celli, leading provider of sustainable solutions for the beverage sector*
    • the acquisition of a majority stake in Jakala, leading Italian martech group*
    • the sale of Neopharmed Gentili, leading Italian pharmaceutical distributor, to a consortium composed by Ardian and NB Renaissance*
    • the reorganization of the shareholdings of Dedalus Group, and the acquisition of a minority stake from the founder*
  • Bridgepoint on several transactions in Italy, including the acquisition of La Gardenia Beauty, the covenant resent of Limoni and the exit from La Gardenia Beauty and Limoni*
  • Dedalus Group (an Ardian portfolio company), on multiple add-on or disposal transactions, including:
    • the acquisition of DXC Technology’s healthcare IT business*
    • the acquisition of Agfa-Gevaert’s healthcare IT business*
    • the acquisition of the “healthcare business” operated by Lutech*
    • the sale of the entire corporate capital of Millennium*
    • the sale of Isoft Nederland and Expertdoc to Total Specific Solutions*
  • Hiab Group, a Finnish listed group active in the manufacturing of load handling machineries, on the acquisition of Effer, an Italian premium knuckle-boom crane manufacturer*
  • Iberis Capital on its investment in D-Orbit, the Italian scale-up specialized in space logistics and other services, in the context of a Euro 150 million Series C financing round*
  • Italmatch Chemicals (an Ardian portfolio company), on multiple add-on transactions, including:
    • the acquisition of the entire share capital of Water Science Technologies*
    • the acquisition of the Afton Chemical’s metalworking fluid business*
    • the take private of Detrex Corporation*
    • the acquisition of the entire share capital of Compass Chemical International from One Rock Capital Partners*
    • the acquisition of Solvay’s phosphonates business and Ionquest 290 and Octyl Phosphonic Acid business*
  • Jakala (an Ardian portfolio company), on multiple add-on transactions, including:
    • the acquisition of the consultancy business unit operated by H-Farm*
    • the acquisition of the entire share capital of FFW Group*
  • Melrose and its portfolio companies on multiple transactions, including:
    • the sale by Broan-Nutone of the entire share capital of Best, leading manufacturer of kitchen hoods, to Electrolux Group*
    • GKN Wheels & Structures Group on the sale of GKN Wheels Carpenedolo, a manufacturer of steel wheels, to Quantum Capital*
    • the acquisition by GKN Sinter Metals Group of the entire corporate capital of Sintec, a leading manufacturer of sintered bearings for industrial appliances*
    • the sale of the entire share capital of Marelli Motori, a leading manufacturer of electric motors and generators, to The Carlyle Group*
  • MooRER, a leading Italian luxury fashion brand, on the sale of a minority stake to Borletti Group*
  • Neopharmed Gentili (an Ardian portfolio company), on multiple add-on transactions, including:
    • the acquisition of entire share capital of Valeas*
    • the acquisition of the lormetazepam product portfolio from Bayer*
    • the acquisition of two portfolios of products from Sanofi*
  • P101, leading Italian venture capital fund, on several transactions including their investment in Teiacare*
  • Trafigura, global leader in the commodities trading, on several activities in Italy, including the establishment of a joint venture with Enoi for the trading of natural gas*
  • Verder Group, on several investments in Italy, including the acquisition of Microdos and the Italian aspects of the acquisition of Sauermann Group*

* Experience prior to joining Ropes & Gray

Areas of Practice